128 related articles for article (PubMed ID: 38102096)
1. Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.
Tong R; Feng X; Sun J; Ling Z; Wang J; Li S; Yang B; Deng J; He G; Wu J
Small; 2024 May; 20(21):e2307273. PubMed ID: 38102096
[TBL] [Abstract][Full Text] [Related]
2. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W
Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
4. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
[TBL] [Abstract][Full Text] [Related]
5. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
[TBL] [Abstract][Full Text] [Related]
6. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
[TBL] [Abstract][Full Text] [Related]
7. DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma.
Li Q; Yuan H; Zhao G; Ou D; Zhang J; Li L; Li S; Feng T; Gu R; Kou Q; Wang Q; Li S; Wang G; Zhao M; Yu H; Qu J; Lin P; Li K
Biochem Pharmacol; 2024 Jul; 225():116251. PubMed ID: 38701867
[TBL] [Abstract][Full Text] [Related]
8. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
9. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
[TBL] [Abstract][Full Text] [Related]
10. Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma.
Su Y; Zhang Z; Lee LTO; Peng L; Lu L; He X; Zhang X
Adv Healthc Mater; 2023 Jan; 12(6):e2202663. PubMed ID: 36653312
[TBL] [Abstract][Full Text] [Related]
11. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
[TBL] [Abstract][Full Text] [Related]
12. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
[TBL] [Abstract][Full Text] [Related]
13. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
14. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
Elkateb AS; Nofal S; Ali SA; Atya HB
Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
[TBL] [Abstract][Full Text] [Related]
15. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
16. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
[TBL] [Abstract][Full Text] [Related]
17. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
[TBL] [Abstract][Full Text] [Related]
18. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
Li J; Li Y; Wang D; Liao R; Wu Z
J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
[TBL] [Abstract][Full Text] [Related]
19. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Duan W; Liu Y
Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
[TBL] [Abstract][Full Text] [Related]
20. Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells.
Wang K; Zhang Z; Tsai HI; Liu Y; Gao J; Wang M; Song L; Cao X; Xu Z; Chen H; Gong A; Wang D; Cheng F; Zhu H
Cell Death Differ; 2021 Apr; 28(4):1222-1236. PubMed ID: 33097833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
